On December 11, 2024, Chroma Medicine and Nvelop Therapeutics announced their merger and subsequent launch of nChroma Bio, a pioneering biotechnology company redefining the future of in vivo targeted genetic medicine to treat a wide array of diseases and bring cures to patients. nChroma also completed a $75 million financing round led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture, and Newpath Partners. Wilson Sonsini Goodrich & Rosati advised Nvelop on intellectual property matters related to the transaction.

The merger combines epigenetic editing and non-viral, programmable delivery to address limitations in the field and broaden the range of treatable conditions. Funds raised from the new financing will be used to drive the lead program to clinical data and build a robust pipeline of next generation hepatic and extrahepatic targeted therapies.

The Wilson Sonsini team that advised Nvelop on IP matters related to the transaction includes Lou Lieto, Chris McAndrew, Jeff Seidel, Wei Huang, and Rachna Ujwal.

For more information, please see Chroma Medicine's and Nvelop's joint news release. Additional coverage can be found on BioPharma Dive and STAT.